医药健康行业2025ASCO(二):国产新药口头汇报量攀升 聚焦肺癌耐药突破/疗法升级

华泰证券
Jun 26, 2025

2025 年ASCO 年会已在6 月初落幕,国产创新药参与度进一步提升。据我们的不完全统计,本次ASCO 会议中约67 项国产创新药研究入选口头汇报,较2024 年增长约35%,占全部临床结果口头汇报内容的20%左右;其中,有9 项国产创新药临床研究入选LBA,较2024 年ASCO 的4 项显著增长。IBI363、MRG003、赛沃替尼、贝莫苏拜单抗、维迪西妥单抗等多款国产新药在LBA 等口头...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10